bioecon Member area
Technology · Health & biomedicine / Therapeutics & platforms

GalNAc-siRNA Conjugates for Hepatocyte Targeting

Chemically stabilized synthetic siRNA coupled to a triantennary N-acetylgalactosamine (GalNAc) ligand, targeting the asialoglycoprotein receptor (ASGPR) for subcutaneous gene silencing in hepatic diseases.

Medicine & Pharmaceuticals Industrial Manufacturing Maturity 8/9 Risk: low Pharma & biologics Biomanufacturing & Bio-industrial Production CH · EU · US · CN verified 2026-11-22 · 1 Sources (0 independent)

1 · What it gives

GalNAc-siRNA conjugates represent the gold standard delivery architecture for hepatocyte-directed RNA interference therapeutics, bypassing the need for complex lipid nanoparticle formulations. The platform couples chemically modified, double-stranded small interfering RNA (typically 21–23 base pairs) to a trivalent branched N-acetylgalactosamine (GalNAc) cluster. This molecular ligand exhibits high affinity (sub-nanomolar avidity) for the asialoglycoprotein receptor (ASGPR, specifically subunits ASGR1 and ASGR2), which is abundantly and uniquely expressed on the sinusoidal membrane of hepatocytes (~500,000 receptors per cell), enabling rapid clathrin-mediated endocytosis.

The therapeutic potency and remarkable longevity (dosing regimens every 3 to 6 months) are driven by comprehensive chemical stabilization of the oligonucleotide backbone. Every ribose sugar is substituted with 2’-O-methyl (2’-OMe) or 2’-deoxy-2’-fluoro (2’-F) modifications arranged in alternating patterns, combined with stereochemically pure phosphorothioate (PS) internucleotide linkages at the terminal positions. Upon receptor-mediated internalization and ASGPR recycling to the plasma membrane, the siRNA escapes endosomes, is cleaved from the GalNAc linker by intracellular esterases, and loads directly into Argonaute-2 (AGO2) within the RNA-induced silencing complex (RISC), triggering catalytic, sequence-specific destruction of target mRNA.

The key directions of this technology are:

  1. Trivalent GalNAc Dendrimer Engineering: Convergent synthesis of branched triantennary GalNAc phosphoramidites with optimized spatial geometry (inter-galactose distances of 15–20 Å) matching the triangular binding pockets of the ASGPR oligomer.
  2. Metabolically Stabilized Oligo Chemistries: Implementing ESC (Enhanced Stabilization Chemistry) and next-gen patterns replacing immunogenic 2’-F with 2’-OMe and 5’-(E)-vinylphosphonate (5’-VP) cap analogs for prolonged RISC residence.
  3. Subcutaneous Auto-Injector Formulation: Aqueous formulation in phosphate-buffered saline (PBS) at high concentrations (>100 mg/mL) with low viscosity (<5 cP), enabling painless, low-volume (1.0–1.5 mL) self-administration.
  4. Extrahepatic ASGPR-Independent Variants: Adapting the multivalent conjugation chemistry to alternative targeting ligands (e.g., integrin-binding peptides, aptamers) for non-hepatic tissues while preserving the core stabilized siRNA architecture.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: Solid-Phase Automated Phosphoramidite Synth.  │
│  (Controlled Pore Glass, 2'-OMe / 2'-F / PS backbones) │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Triantennary GalNAc Cluster Solid Coupling    │
│  (Solid-support or post-cleavage click / ester ligation)│
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: Anion-Exchange & Reverse-Phase Purification   │
│  (Preparative AX-HPLC, desalting, >98.5% purity)       │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: Duplex Annealing & Stoichiometric QC          │
│  (Sense & antisense equimolar hybridization, LC-MS)    │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: Sterile Filtration, Lyophilization & Fill     │
│  (0.22 um PES filtration, PBS reconstitution, PFS)     │
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Building Block & Phosphoramidite SynthesisHigh-purity chemical synthesis of 2’-modified ribonucleosides, phosphitylation, and triantennary GalNAc branch units.In: Nucleoside precursors, phosphitylating agents, GalNAc ligand synthons.
Out: HPLC-purified phosphoramidites and GalNAc-CPG solid support.
Automated Solid-Phase RNA AssemblySequential stepwise coupling of sense and antisense strands on large-scale (100–500 mmol) synthesizer columns with DMT deprotection and sulfurization.In: Phosphoramidites, solid support, activators, sulfurizing reagents.
Out: Fully protected, support-bound RNA single strands.
Cleavage, Deprotection & Crude SeparationAqueous ammonia/methylamine treatment to cleave the linker, remove cyanoethyl and base-protecting groups, followed by fluoride desilylation.In: Crude cleaving reagents, triethylamine trihydrofluoride.
Out: Crude aqueous RNA single strands containing GalNAc conjugate.
Chromatographic Polishing & Duplex AnnealingPreparative strong anion-exchange (SAX) HPLC and tangential flow filtration (TFF) desalting, followed by controlled thermal duplex annealing.In: Crude oligo pools, sodium perchlorate buffer, ultrafiltration cassettes.
Out: Purified double-stranded GalNAc-siRNA bulk active substance.
Sterile Fill-Finish & Analytical ReleaseAseptic compounding in PBS (pH 7.4), terminal 0.22 um PES filtration, and automated filling into pre-filled glass syringes (PFS) or vials.In: Duplex bulk drug substance, excipient buffers, glass syringes.
Out: Final commercial injectable drug product meeting USP <788> standards.

Cross-cutting technologies of the sector:

  • Process Analytical Technology (PAT) in Oligo Synthesis: In-line UV-Vis trityl monitoring and real-time conductivity sensing verifying coupling efficiency (>99.2% per cycle).
  • High-Resolution Orbitrap LC-MS Deconvolution: Exact mass verification of full-length oligo sequences and characterization of n-1 deletion and phosphorothioate stereoisomer impurities.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 4 steps

  1. 1
    Triantennary GalNAc ligand synthesis
    Convergent synthesis of branched trivalent GalNAc clusters optimized for sub-nanomolar ASGPR avidity.
  2. 2
    Phosphoramidite oligonucleotide synthesis
    Automated RNA solid-phase synthesis with 2’-OMe, 2’-F, and phosphorothioate stability modifications.
  3. 3
    Subcutaneous formulation
    Formulating aqueous, sterile, room-temperature stable injectable solutions without lipid excipients.
  4. 4
    Durable hepatic mRNA knockdown
    Achieving up to 6 months of sustained target mRNA and protein suppression in liver tissue per single dose.

4 · Who delivers

Matched suppliers (matched automatically)

NovartisSwitzerlandProduceractive
Lonza GroupSwitzerlandProduceractive
GSKUnited KingdomProduceractive
Jiangsu Hengrui MedicineChinaProduceractive
Daiichi SankyoJapanProduceractive
Bluestem BiosciencesUnited StatesProduceractive
Global BioenergiesFranceProduceractive
HaesinSouth KoreaResearch / RTOactive
PUEVIT GmbHGermanyEquipmentactive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Alnylam Pharmaceuticals🇺🇸 United StatesGivlaari, Oxlumo, AmvuttraPioneer of ESC GalNAc-siRNA platformcommercial
Novartis🇨🇭 SwitzerlandLeqvio (inclisiran)Biannual PCSK9 siRNA for hyperlipidemiacommercial
Silence Therapeutics🇬🇧 United KingdomZerlasiran (SLN360), DivesiranProprietary mRNAi GOLD GalNAc platformclinical
Sirnaomics🇺🇸 United StatesSTP122G, GalNAc platformsDual-targeting siRNA conjugates for liver fibrosisclinical
Suzhou Ribo Life Science🇨🇳 ChinaRBD7022, RIBO-GalSTARLeading Chinese clinical GalNAc platformclinical
Bachem🇨🇭 SwitzerlandCommercial Oligo API ManufacturingLarge-scale solid-phase synthesizer suitescommercial
CordenPharma🇩🇪 GermanyOligo & Conjugation CDMOIntegrated lipid, peptide, and GalNAc synthesiscommercial

5 · Rules & route to market

United States

Commercial leadership, cardiovascular and rare disease pipelines#

  • FDA Regulatory Milestones: FDA approvals of Givlaari (givosiran), Oxlumo (lumasiran), Leqvio (inclisiran), and Amvuttra (vutrisiran) established the CDER regulatory approval roadmap under 505(b)(1) NDA pathways.
  • Mass-Market Indications: Transition from ultra-rare hepatic diseases to high-prevalence cardiovascular indications (e.g., hypercholesterolemia, Lp(a) lowering, hypertension via angiotensinogen targeting).
  • Manufacturing Infrastructure: Large-scale automated synthesis facilities operating in Colorado, Massachusetts, and North Carolina capable of multi-hundred-kilogram annual synthetic oligo output.

European Union

Swiss and European CMO powerhouses, EMA PRIME designations#

  • Contract CDMO Scaling: Global contract manufacturing hubs (Lonza in Visp/Basel, Bachem in Bubendorf, CordenPharma) driving multi-ton peptide and oligonucleotide synthesis capabilities.
  • EMA Approval Precedents: Successful centralized marketing authorizations across all 27 EU member states with streamlined post-authorization safety monitoring (PASS).
  • Green Chemistry Initiatives: European consortiums developing eco-friendly peptide/oligo coupling reagents that replace toxic N,N-dimethylformamide (DMF) with bio-based green solvents (2-MeTHF, Cyrene).

China

Rapid biosimilar and novel target expansion, NMPA fast-track#

  • NMPA Priority Review Status: Domestic biopharmas leveraging China’s Center for Drug Evaluation (CDE) priority review channels for hepatic target pipelines (HBV clearance, hyperlipidemia, PCSK9/ANGPTL3).
  • Regional Oligo Manufacturing Hubs: High-capacity solid-phase synthesis and reagent clusters established across Jiangsu (Suzhou BioBAY) and Shanghai Zhangjiang Hi-Tech Park.
  • Clinical Breakthroughs in HBV: State-funded National Science and Technology Major Projects backing novel GalNAc-siRNA conjugates achieving sustained HBsAg seroclearance in chronic hepatitis B patients.

6 · Money: tenders & grants

No open tender or grant matched right now.

7 · Tech stack & innovations

  1. Triantennary GalNAc Cluster Scaffolding:
    • Utilizes tris-hydroxymethyl aminomethane (TRIS) or branched pentaerythritol cores linked via hydrophilic PEG or alkyl spacers to 3 terminal alpha-D-GalNAc residues.
    • Optimized spatial geometry achieves sub-nanomolar dissociation constants (Kd = 0.1–1.0 nM) for hepatic ASGPR complexes.
  2. Enhanced Stabilization Chemistry (ESC):
    • Comprehensive alternating 2’-OMe / 2’-F chemical modification motifs eliminating endo- and exo-nuclease degradation in serum.
    • Stereochemically configured terminal phosphorothioate internucleotide bonds protecting terminal ends from exonucleolytic degradation.
  3. In-Line PAT & Solid-Phase Synthesizers:
    • Automated high-pressure flow-through synthesizers with dynamic axial compression (DAC) columns operating at pressures up to 100 bar.
    • Conductometric trityl monitoring providing real-time feedback and closed-loop control of deblocking, coupling, and capping cycles.

Sources 1 · 0 independent · 1 producer sites

Producers' own sites 1

  1. www.swissbiotech.org producer checked 2026-11-22